Director Kapil Dhingra filed a Form 144 notice of proposed sale of 16,500 shares of Replimune Group Inc. common stock, with an approximate sale date of November 2, 2026, through J.P. Morgan Securities LLC.

Key Highlights

  • Seller: Kapil Dhingra, a director of Replimune Group Inc., is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 16,500 shares of Replimune Group Inc. common stock, with an aggregate market value of $292,875.
  • Source of shares: The securities were acquired through stock options from the issuer on November 2, 2026, with cash payment on the same date.
  • Total shares outstanding: 94,800,404 shares of common stock outstanding, according to the filing.
  • Broker: J.P. Morgan Securities LLC, 270 Park Avenue, 10th Floor, New York, NY 10017, is named as the broker for the proposed sale.
  • Prior sales: The filing reports nothing to report for securities sold during the past three months.

Dhingra's Proposed Rule 144 Sale of Replimune Common Stock

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Kapil Dhingra, identified as a director of Replimune Group Inc. (NASDAQ:REPL), proposed the sale of 16,500 shares of the company's common stock. The approximate date of sale listed in the filing is November 2, 2026, and the broker named to execute the transaction is J.P. Morgan Securities LLC, acting as agent and attorney-in-fact for Dhingra.

The filing discloses that the 16,500 shares were acquired via stock options from the issuer, with both the acquisition date and the date of payment listed as November 2, 2026. The aggregate market value of the shares proposed for sale is stated as $292,875. At the time of the filing, total shares of common stock outstanding for Replimune Group Inc. were reported as 94,800,404.

The filing further discloses that there are no securities of the issuer sold by Dhingra during the past three months to report. By signing the notice, the filing states that the selling person "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." Replimune Group Inc. is headquartered at 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801.

What Was Disclosed

Kapil Dhingra, a director of Replimune Group Inc., filed a Form 144 notice proposing the sale of 16,500 shares of common stock with an aggregate market value of $292,875, acquired through stock options, with a proposed sale date of November 2, 2026.